Study record
NMN, NAD⁺ metabolism, and arterial stiffness (2023)
Human RCT — biomarker endpoint
○ Evidence tier 4 — Human RCT — biomarker endpoint
Record verify: primary source pending
| Design | Randomized, double-blind, placebo-controlled trial (biomarker) |
| DOI | 10.1038/s41598-023-29787-3 |
| Citation status | doi verified via Crossref 2026-07-12 (Sci Rep 2023;13, 'Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial'). PMID + NCT: needs_primary_fulltext. |
Five-qualifier claim
| Species / population | Middle-aged and older adults (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral NMN (long-term supplementation) over the trial period. |
| Comparator / duration | Placebo-controlled, double-blind, randomized. |
| Endpoint / numeric result | Changes in NAD+ metabolism and an arterial-stiffness measure after long-term NMN supplementation. |
| What it did NOT establish | Biomarker/surrogate vascular endpoints — no functional-disability, disease-outcome, or lifespan endpoint. |
Interventions
Primary reference
https://doi.org/10.1038/s41598-023-29787-3
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.